切换至 "中华医学电子期刊资源库"

中华肺部疾病杂志(电子版) ›› 2022, Vol. 15 ›› Issue (01) : 119 -122. doi: 10.3877/cma.j.issn.1674-6902.2022.01.036

综述

呼出气一氧化氮的研究进展
李江华1, 李力1, 何勇1   
  1. 1. 400042 重庆,中国人民解放军陆军特色医学中心
  • 收稿日期:2021-12-11 出版日期:2022-02-25

Research progress of exhaled nitric oxide

Jianghua Li1, Li Li1, Yong He1   

  • Received:2021-12-11 Published:2022-02-25
引用本文:

李江华, 李力, 何勇. 呼出气一氧化氮的研究进展[J]. 中华肺部疾病杂志(电子版), 2022, 15(01): 119-122.

Jianghua Li, Li Li, Yong He. Research progress of exhaled nitric oxide[J]. Chinese Journal of Lung Diseases(Electronic Edition), 2022, 15(01): 119-122.

1
Horvath I, Barnes PJ, Loukides S, et al. A European Respiratory Society technical standard: exhaled biomarkers in lung disease[J]. Eur Respir J, 2017, 49(4): 1600965.
2
Mahr TA, Malka J, Spahn JD. Inflammometry in pediatric asthma: a review of fractional exhaled nitric oxide in clinical practice[J]. Allergy Asthma Proc, 2013, 34(3): 210-219.
3
Ludviksdottir D, Diamant Z, Alving K, et al. Clinical aspects of using exhaled NO in asthma diagnosis and management[J]. Clin Respir J, 2012, 6(4): 193-207.
4
Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications[J]. Am J Respir Crit Care Med, 2011, 184(5): 602-615.
5
李江华,李 力,王玉波,等. 呼出气一氧化氮和血嗜酸性粒细胞对哮喘患者气道高反应性程度的预测价值[J/CD]. 中华肺部疾病杂志(电子版), 2021, 14(1): 24-30.
6
蔡柏蔷,李龙芸. 协和呼吸病学.第2版[M]. 中国协和医科大学出版社,2011: 413-420.
7
Kim HB, Eckel SP, Kim JH, et al. Exhaled NO: Determinants and clinical application in children with allergic airway disease[J]. Allergy Asthma Immunol Res, 2016, 8(1): 12-21.
8
Manna A, Montella S, Maniscalco M, et al. Clinical application of nasal nitric oxide measurement in pediatric airway diseases[J]. Pediatr Pulmonol, 2015, 50(1): 85-99.
9
Logotheti H, Pourzitaki C, Tsaousi G, et al. The role of exhaled nitric oxide in patients with chronic obstructive pulmonary disease undergoing laparotomy surgery-The noxious study[J]. Nitric Oxide, 2016, 61: 62-68.
10
Klinger JR, Kadowitz PJ. The nitric oxide pathway in pulmonary vascular disease[J]. Am J Cardiol, 2017, 120(8S): S71-S79.
11
Bjermer L, Alving K, Diamant Z, et al. Current evidence and future research needs for FeNO measurement in respiratory diseases[J]. Respir Med, 2014, 108(6): 830-841.
12
中国医师协会呼吸医师分会. 无创气道炎症评估支气管哮喘的临床应用中国专家共识[J]. 中华结核和呼吸杂志2015, 38(5): 329-341.
13
Malinovschi A, Backer V, Harving H, et al. The value of exhaled nitric oxide to identify asthma in smoking patients with asthma-like symptoms[J]. Respir Med, 2012, 106(6): 794-801.
14
Alving K, Malinovschi A. Basic aspects of exhaled nitric oxide[J]. Eur Respir Monograph, 2011, 49: 1-31.
15
Prieto L, Ruiz-Jimenez L, Marin J. The effect of spirometry on bronchial and alveolar nitric oxide in subjects with asthma[J]. J Asthma, 2013, 50(6): 623-628.
16
Romero KM, Robinson CL, Baumann LM, et al. Role of exhaled nitric oxide as a predictor of atopy[J]. Respir Res, 2013, 14: 48.
17
Global strategy for asthma management and prevention 2019 update .2019.

URL    
18
李志伟,马千里,王长征. 支气管哮喘的炎症表型及其临床意义[J/CD]. 中华肺部疾病杂志(电子版), 2013, 6(4): 41-45.
19
Mcnicholl DM, Stevenson M, Mcgarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma[J]. Am J Respir Crit Care Med, 2012, 186(11): 1102-1108.
20
Menzella F, Lusuardi M, Galeone C, et al. Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential[J]. Ther Adv Chronic Dis, 2016, 7(6): 260-277.
21
Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma[J]. N Engl J Med, 2011, 365(12): 1088-1098.
22
Corcuera-Elosegui P, Sardon-Prado O, Aldasoro-Ruiz A, et al. Inflammatory patterns in asthmatic children based on alveolar nitric oxide determination[J]. Arch Bronconeumol, 2015, 51(6): 279-284.
23
Muraro A, Lemanske RJ, Hellings PW, et al. Precision medicine in patients with allergic diseases: airway diseases and atopic dermatitis-PRACTALL document of the european academy of allergy and clinical immunology and the american academy of allergy, asthma & immunology[J]. J Allergy Clin Immunol, 2016, 137(5): 1347-1358.
24
Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases[J]. Lancet, 2018, 391(10118): 350-400.
25
Magni C, Chellini E, Zanasi A. Cough variant asthma and atopic cough[J]. Multidiscip Respir Med, 2010, 5(2): 99-103.
26
Kim SH, Jeong JH, Kwak HJ, et al. Measurement of nasal nitric oxide is useful for the diagnosis of sinusitis-induced prolonged cough[J]. Tohoku J Exp Med, 2011, 223(2): 145-151.
27
Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health[CPH] study): a national cross-sectional study[J]. Lancet, 2018, 391(10131): 1706-1717.
28
任成山,王关嵩,钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
29
Martinez FD. Early-life origins of chronic obstructive pulmonary disease[J]. N Engl J Med, 2016, 375(9): 871-878.
30
Lazar Z, Kelemen A, Galffy G, et al. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease[J]. J Breath Res, 2018, 12(3): 36017.
31
Santus P, Radovanovic D, Mascetti S, et al. Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD[J]. Pharmacol Res2018133:160-169.
32
Alcazar-Navarrete B, Castellano MF, Santiago DP, et al. Alveolar and bronchial nitric oxide in chronic obstructive pulmonary disease and asthma-COPD overlap[J]. Arch Bronconeumol, 2018, 54(8): 414-419.
33
Shapiro AJ, Davis SD, Polineni D, et al. Diagnosis of primary ciliary dyskinesia. an official american thoracic society clinical practice guideline[J]. Am J Respir Crit Care Med, 2018, 197(12): e24-e39.
34
Lucas JS, Barbato A, Collins SA, et al. European respiratory society guidelines for the diagnosis of primary ciliary dyskinesia[J]. Eur Respir J, 2017, 49(1): 1601090.
35
中华医学会儿科学分会呼吸学组疑难少见病协作组,国家呼吸系统疾病临床医学研究中心,编辑委员会中华实用儿科临床杂志. 儿童原发性纤毛运动障碍诊断与治疗专家共识[J]. 中华实用儿科临床杂志2018, 33(2): 94-99.
36
Brooks EA, Massanari M. Cost-effectiveness analysis of monitoring fractional exhaled nitric oxide (FeNO) in the management of asthma[J]. Manag Care, 2018, 27(7): 42-48.
37
Arnold RJ, Massanari M, Lee TA, et al. A review of the utility and cost effectiveness of monitoring fractional exhaled nitric oxide (FeNO) in asthma management[J]. Manag Care, 2018, 27(7): 34-41.
[1] 马锦芳, 何正光, 郑劲平. 盐酸氨溴索雾化吸入治疗慢性阻塞性肺疾病黏痰症患者的疗效和安全性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 568-574.
[2] 程炜炜, 张青, 张诚实, 冯契靓, 陈荣荣, 赵云峰. 全身免疫炎症指数与慢性阻塞性肺疾病急性加重期病情严重程度相关性分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 580-584.
[3] 杨万荣, 任治坤, 时新颍. 沙丁胺醇雾化吸入脾多肽治疗AECOPD的疗效分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 609-612.
[4] 赖乾德, 吕相琴, 蔺洋, 刘媛梅, 赵春艳, 李琦. 肝素结合蛋白对慢性阻塞性肺疾病预后预测分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 613-616.
[5] 王微, 丁霖, 陈茜, 呼延欣, 闫蓓. 综合治疗对慢性阻塞性肺疾病的疗效及转归影响分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 621-624.
[6] 方晓玉, 王婷, 赵珊, 陈锋. HALP指数对AECOPD并发呼吸衰竭患者ICU结局的预测意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 639-641.
[7] 郭少琳, 郭建英, 左秀萍, 高苗. 慢性阻塞性肺疾病康复训练依从性影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 652-654.
[8] 白若靖, 郭军. 维生素D对肺部疾病临床意义的研究进展[J]. 中华肺部疾病杂志(电子版), 2024, 17(04): 659-662.
[9] 孔令梅, 徐晓媛, 马丽颖. 慢性阻塞性肺疾病认知衰弱危险因素及预后分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 407-410.
[10] 徐艳, 江秀娟, 王超, 江圆满. 股直肌剪切波弹性成像对COPD并发肌少症的诊断意义[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 454-457.
[11] 黄映兰, 骆丽萍, 郭慧玲, 袁麟标. 慢性阻塞性肺疾病糖皮质激素治疗反应性的影响因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 469-471.
[12] 杨坤, 赵景成, 吴永强. 无创呼吸机在慢性阻塞性肺疾病并发呼吸衰竭救治的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(03): 481-483.
[13] 宋素莉, 贺英华, 陈丽娟. COPD并发吸入性CAP危险因素及病原菌分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 264-267.
[14] 陈婷婷, 李春娟. 经鼻高流量湿化氧疗治疗AECOPD伴Ⅱ型呼吸衰竭的临床分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 276-279.
[15] 周文欢, 杨黎. AECOPD低钠血症发生风险及预测因素分析[J]. 中华肺部疾病杂志(电子版), 2024, 17(02): 313-315.
阅读次数
全文


摘要